BCL2 and breast carcinoma: Additionally, in models of MYC-driven breast cancer, the combined use of metformin with venetoclax or navitoclax suppressed tumor cell growth effectively and induced immune infiltration into tumors, which adds new insight into the strategy of cotargeting AMPK and BCL-2 to enhance synergy [132].